BRPI0817445A2 - composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto - Google Patents

composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto

Info

Publication number
BRPI0817445A2
BRPI0817445A2 BRPI0817445A BRPI0817445A BRPI0817445A2 BR PI0817445 A2 BRPI0817445 A2 BR PI0817445A2 BR PI0817445 A BRPI0817445 A BR PI0817445A BR PI0817445 A BRPI0817445 A BR PI0817445A BR PI0817445 A2 BRPI0817445 A2 BR PI0817445A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BRPI0817445A
Other languages
English (en)
Inventor
Dulce Maria Garrido
Francis X Tavares
Pierette Banker
Scott Howard Dickerson
Stephen Andrew Thomson
Steven Meagher Sparks
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0817445A2 publication Critical patent/BRPI0817445A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0817445A 2007-09-28 2008-09-25 composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto BRPI0817445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586507P 2007-09-28 2007-09-28
PCT/US2008/077626 WO2009045831A1 (en) 2007-09-28 2008-09-25 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof

Publications (1)

Publication Number Publication Date
BRPI0817445A2 true BRPI0817445A2 (pt) 2015-10-27

Family

ID=40120238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817445A BRPI0817445A2 (pt) 2007-09-28 2008-09-25 composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto

Country Status (16)

Country Link
US (1) US20100234433A1 (pt)
EP (1) EP2197845A1 (pt)
JP (1) JP2010540553A (pt)
KR (1) KR20100075568A (pt)
CN (1) CN101861303A (pt)
AU (1) AU2008309004A1 (pt)
BR (1) BRPI0817445A2 (pt)
CA (1) CA2701020A1 (pt)
CO (1) CO6321157A2 (pt)
CR (1) CR11397A (pt)
DO (1) DOP2010000088A (pt)
EA (1) EA201000392A1 (pt)
MA (1) MA31775B1 (pt)
MX (1) MX2010003442A (pt)
WO (1) WO2009045831A1 (pt)
ZA (1) ZA201002182B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236757T3 (es) * 1995-11-24 2005-07-16 Glaxosmithkline S.P.A. Derivados de quinolina.
US20070249670A1 (en) * 2004-11-09 2007-10-25 Smithkline Beecham Corporation Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof

Also Published As

Publication number Publication date
EP2197845A1 (en) 2010-06-23
CN101861303A (zh) 2010-10-13
ZA201002182B (en) 2011-05-25
CO6321157A2 (es) 2011-09-20
EA201000392A1 (ru) 2010-10-29
US20100234433A1 (en) 2010-09-16
AU2008309004A1 (en) 2009-04-09
DOP2010000088A (es) 2010-07-15
CA2701020A1 (en) 2009-04-09
MA31775B1 (fr) 2010-10-01
MX2010003442A (es) 2010-04-21
WO2009045831A1 (en) 2009-04-09
JP2010540553A (ja) 2010-12-24
CR11397A (es) 2010-05-24
KR20100075568A (ko) 2010-07-02

Similar Documents

Publication Publication Date Title
BRPI0817721A2 (pt) Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0914927A2 (pt) composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BR122020011920A2 (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0811275A2 (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0812521A2 (pt) Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0919488A2 (pt) composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI1009022A2 (pt) "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI0815493A2 (pt) Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0718155A2 (pt) Composto, uso de um composto, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0817445A2 (pt) composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto
BRPI1007654A2 (pt) composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI0814163A2 (pt) Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.